Correcting genetic mutations in cystic fibrosis airways
Official title: Adenine Base Edited Correction of Cystic Fibrosis Airways
Funded at University of Iowa · NIH-11003727 · Data updated 2026-11-12
This study is exploring a new way to fix the genetic problems that cause cystic fibrosis by using a special tool to help your body make the proteins it needs for healthy lungs, and it's testing two different ways to deliver this tool to the cells in your airways.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $619,643 |
| NIH project number | 5R01HL171035-02 |
| Project ID | NIH-11003727 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cystic fibrosis who have specific genetic mutations that prevent the production of functional CFTR proteins.
✕Less likely to help
Patients with cystic fibrosis who do not have the targeted genetic mutations or those who are already benefiting from existing therapies may not receive any benefit from this research.
What this research studies
This research focuses on developing a new method to correct genetic mutations that cause cystic fibrosis (CF) by using a specialized tool called an Adenine Base Editor (ABE). The ABE works by converting specific genetic material to produce the necessary proteins for lung function, particularly in patients whose CFTR proteins are only partially produced. The researchers aim to effectively deliver this editing tool to airway cells using two different delivery methods: adeno-associated viruses (AAVs) and viral-like particles (VLPs). By comparing these methods, the study seeks to find the most effective way to treat CF at the genetic level.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for cystic fibrosis patients who currently have no effective therapies available.
How similar studies have gone: Other research has shown promise in using gene editing techniques for similar genetic conditions, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of Iowa
Iowa City, United States Active
Researchers
- Principal investigator: Sinn, Patrick L — University of Iowa
- Study coordinator: Sinn, Patrick L
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.